Location, Spreading and Oral Corticosteroids are Associated with Insomnia in Vitiligo Patients: A Case-Control Study.
insomnia
insomnia severity index
psychodermatology
risk factors
sleep disorder
vitiligo
Journal
Clinical, cosmetic and investigational dermatology
ISSN: 1178-7015
Titre abrégé: Clin Cosmet Investig Dermatol
Pays: New Zealand
ID NLM: 101543449
Informations de publication
Date de publication:
2021
2021
Historique:
received:
05
06
2021
accepted:
13
07
2021
entrez:
11
8
2021
pubmed:
12
8
2021
medline:
12
8
2021
Statut:
epublish
Résumé
Vitiligo can cause disfiguration, impair the social function of the patients and induce physiological burdens. However, limited research about the health-related quality of life has been conducted in vitiligo patients' sleeping conditions. To evaluate the prevalence, severity, and risk factors of insomnia in vitiligo patients. This case-control study was performed in March 2021. An online survey questionnaire including baseline information and the sleep-related instrument was sent to 762 vitiligo patients. The vitiligo-related evaluation was conducted by online video interview. According to whether having insomnia or not, patients were grouped and compared their clinical and demographic characteristics. The logistic regression model was conducted to analyze the risk factors for insomnia. A total of 409 patients were included. About 49.9% of patients (204/409) experienced insomnia. About 55.9% (114/204) of the insomnia in vitiligo patients was adjustment sleep disorder caused by vitiligo. Development, aggravation, or recurrence of vitiligo were deemed as the first reason for insomnia in 71.1% of the sample (81/114). There were significant differences in age (32.1±4.1 vs 27.9±4.2 years, P < 0.001), the percentage of female (62.8% vs 49.3%, P=0.006) and working in the urban areas (77.0% vs 66.3%, P = 0.017), vitiligo in face and neck (67.2% vs 48.8%, P < 0.001), progression in vitiligo (65.7% vs 49.3%, P=0.001), oral corticosteroids (25.0% vs 16.6%, P=0.036) and depression (5.4% vs 0.5%, P = 0.003) between groups. After adjusting for gender, age and comorbidity, the multivariate logistic regression revealed that vitiligo in face and neck (OR=2.62; P=0.032), progression in vitiligo (OR=2.50; P=0.002), and oral corticosteroids (OR=2.71; P=0.021) remained risk factors for insomnia in vitiligo patients. Insomnia is prevalent in vitiligo patients. Dermatologists should identify this condition carefully, especially humanistic factors in social life, and perform individualized "non-drug" treatment.
Sections du résumé
BACKGROUND
BACKGROUND
Vitiligo can cause disfiguration, impair the social function of the patients and induce physiological burdens. However, limited research about the health-related quality of life has been conducted in vitiligo patients' sleeping conditions.
OBJECTIVE
OBJECTIVE
To evaluate the prevalence, severity, and risk factors of insomnia in vitiligo patients.
METHODS
METHODS
This case-control study was performed in March 2021. An online survey questionnaire including baseline information and the sleep-related instrument was sent to 762 vitiligo patients. The vitiligo-related evaluation was conducted by online video interview. According to whether having insomnia or not, patients were grouped and compared their clinical and demographic characteristics. The logistic regression model was conducted to analyze the risk factors for insomnia.
RESULTS
RESULTS
A total of 409 patients were included. About 49.9% of patients (204/409) experienced insomnia. About 55.9% (114/204) of the insomnia in vitiligo patients was adjustment sleep disorder caused by vitiligo. Development, aggravation, or recurrence of vitiligo were deemed as the first reason for insomnia in 71.1% of the sample (81/114). There were significant differences in age (32.1±4.1 vs 27.9±4.2 years, P < 0.001), the percentage of female (62.8% vs 49.3%, P=0.006) and working in the urban areas (77.0% vs 66.3%, P = 0.017), vitiligo in face and neck (67.2% vs 48.8%, P < 0.001), progression in vitiligo (65.7% vs 49.3%, P=0.001), oral corticosteroids (25.0% vs 16.6%, P=0.036) and depression (5.4% vs 0.5%, P = 0.003) between groups. After adjusting for gender, age and comorbidity, the multivariate logistic regression revealed that vitiligo in face and neck (OR=2.62; P=0.032), progression in vitiligo (OR=2.50; P=0.002), and oral corticosteroids (OR=2.71; P=0.021) remained risk factors for insomnia in vitiligo patients.
CONCLUSION
CONCLUSIONS
Insomnia is prevalent in vitiligo patients. Dermatologists should identify this condition carefully, especially humanistic factors in social life, and perform individualized "non-drug" treatment.
Identifiants
pubmed: 34377005
doi: 10.2147/CCID.S322963
pii: 322963
pmc: PMC8349229
doi:
Types de publication
Journal Article
Langues
eng
Pagination
971-980Informations de copyright
© 2021 Liu et al.
Déclaration de conflit d'intérêts
All authors report no conflict of interest.
Références
Eur J Dermatol. 2008 Mar-Apr;18(2):165-8
pubmed: 18424376
Ann Med. 2015;47(6):482-91
pubmed: 26224201
J Sleep Res. 1997 Sep;6(3):179-88
pubmed: 9358396
Int J Dermatol. 1993 Oct;32(10):753-7
pubmed: 8225724
Cutis. 1987 Jun;39(6):493-4
pubmed: 3608575
Br J Dermatol. 2017 Sep;177(3):708-718
pubmed: 27878819
Sleep. 2018 Sep 1;41(9):
pubmed: 29955877
Rev Med Brux. 2007 Jan-Feb;28(1):11-20
pubmed: 17427674
Sleep Med. 2017 Jul;35:62-66
pubmed: 28619183
J Am Acad Dermatol. 2017 Jul;77(1):1-13
pubmed: 28619550
Br J Med Psychol. 1999 Sep;72 ( Pt 3):385-96
pubmed: 10524722
Lancet. 2015 Jul 4;386(9988):74-84
pubmed: 25596811
Eur J Epidemiol. 2017 Oct;32(10):881-891
pubmed: 28856478
Clin Cosmet Investig Dermatol. 2020 Aug 04;13:511-520
pubmed: 32801827
Gen Hosp Psychiatry. 1979 Apr;1(1):73-7
pubmed: 499777
J Psychopharmacol. 2019 Aug;33(8):923-947
pubmed: 31271339
J Eur Acad Dermatol Venereol. 2018 Aug;32(8):1343-1351
pubmed: 29222958
J Dermatol. 2001 Aug;28(8):419-23
pubmed: 11560158
J Am Acad Dermatol. 1990 Feb;22(2 Pt 1):221-2
pubmed: 2312803
Clin Neuropharmacol. 1992;15 Suppl 1 Pt A:588A-589A
pubmed: 1354065
Acta Derm Venereol. 2019 Feb 1;99(2):175-180
pubmed: 30307027
Rev Bras Epidemiol. 2019 Feb 04;21Suppl 02(Suppl 02):e180018
pubmed: 30726363
Sleep. 2011 May 01;34(5):601-8
pubmed: 21532953
JAMA. 2013 Feb 20;309(7):706-16
pubmed: 23423416
Neurotherapeutics. 2012 Oct;9(4):687-701
pubmed: 22976557
Arch Dermatol. 1999 Apr;135(4):407-13
pubmed: 10206047
Dermatol Ther. 2020 May;33(3):e13418
pubmed: 32297399
Dermatol Clin. 2018 Jul;36(3):277-292
pubmed: 29929599
Sleep. 2003 May 1;26(3):267-72
pubmed: 12749544
Health Qual Life Outcomes. 2020 Feb 3;18(1):20
pubmed: 32013982
Sleep Med Rev. 2016 Oct;29:63-75
pubmed: 26624228
J Am Acad Dermatol. 2008 Mar;58(3):415-20
pubmed: 18280338
Indian J Dermatol Venereol Leprol. 2013 Sep-Oct;79(5):679-85
pubmed: 23974584
J Allergy Clin Immunol. 2005 Dec;116(6):1200-1
pubmed: 16337445
Sleep. 2015 Apr 01;38(4):581-6
pubmed: 25669189
Neuropsychobiology. 1986;16(4):198-204
pubmed: 3614616
Sleep Med. 2003 Jul;4(4):343-5
pubmed: 14592308
Arch Dermatol. 2004 Jun;140(6):677-83
pubmed: 15210457
Dermatol Clin. 2017 Apr;35(2):117-128
pubmed: 28317521
J Gend Stud. 2019;28(4):402-413
pubmed: 31223201